We have observed
14 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after September 18, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
Prolonged release gabapentin tablet formulation whose ability to stay in the stomach is improved
Racecadotril and pharmaceutical compositions thereof
An oral pharmaceutical composition comprising ibuprofen, ibuprofen sodium dihydrate, pseudoephedrine hydrochloride and chlorpheniramine maleate
AQUEOUS SOLUTION COMPOSITION CONTAINING IPRATROPIUM AND OXYMETAZOLINE
Soluble and dispersible pharamaceutical deferasirox formulation
GEL SYSTEMS CONTAINING VANCOMYCIN MICROSPHERES FOR CONTROLLED DRUG RELEASE AND SERRATIOPEPTIDASE
POWDER FORMULATION OF VALGANCICLOVIR
NANOPARTICLE FORMULATION CONTAINING FARNESYLTHIOSALICYLIC ACID (SALIRASIB)
CEFDITOREN PIVOXIL COMPOSITIONS WITH IMPROVED STABILITY AND PRODUCTION METHODS THEREOF
A STABLE BILAYER PHARMACEUTICAL TABLET COMPOSITIONS COMPRISING FIXED DOSE OF IRBESARTAN AND AMLODIPINE
ORAL PHARMACEUTICAL COMPOSITION COMPRISING OTILONIUM BROMIDE AND SIMETHICONE WITH CERTAIN BULK DENSITY AND IMPROVED DISSOLUTION CHARACTERISTICS
CONTROLLED RELEASE PROPIVERINE FORMULATIONS
TOPICAL MINOXIDIL COMPOSITION